Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.

NCT00937352 is registered in ClinicalTrials.gov with JANSSEN Alzheimer Immunotherapy Research & Development, LLC as lead sponsor.

NCT NCT00937352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Extension, Multicenter, Double-Blind, Long-Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Alzheimer's Disease Who Participated in Study ELN115727-301 or Study ELN115727-302.
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2009
Completion date
September 30, 2012
Enrollment
896 (actual)
Sites
191

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease